# China NMPA Drug Inspection - Xiangyang Honghua Traditional Chinese Medicine Pieces Co., Ltd. - Angelica pubescens

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/xiangyang-honghua-traditional-chinese-medicine-pieces-co-ltd/b84d18be-a291-4ec5-8a92-8dcd25ccb02b/
Source feed: China

> China NMPA drug inspection for Xiangyang Honghua Traditional Chinese Medicine Pieces Co., Ltd. published August 03, 2018. Drug: Angelica pubescens. In an announcement issued on August 3, 2018 (NMPA Announcement No. 69 of 2018), the National Medical Products Administra

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 69 of 2018 from the National Medical Products Administration regarding 11 batches of drugs that did not meet the requirements.
- Company Name: Xiangyang Honghua Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-08-03
- Drug Name: Angelica pubescens
- Inspection Finding: The drug did not meet the regulations, and the non-compliant items included sulfur dioxide residue and content determination.
- Action Taken: Relevant drug regulatory authorities have taken control measures such as sealing and seizing, requiring companies to suspend sales and use, recall products, and rectify the situation. Meanwhile, relevant provincial drug regulatory authorities will initiate investigations into the illegal activities and complete the investigation and handling within three months, publicly disclosing the results.
- Summary: In an announcement issued on August 3, 2018 (NMPA Announcement No. 69 of 2018), the National Medical Products Administration (NMPA) reported that 11 batches of drugs from seven companies, including Anyang Lude Pharmaceutical Co., Ltd., were found to be non-compliant. The findings, based on testing by provincial institutes, revealed significant quality control issues.Specifically, six batches of Angelica pubescens from six companies, including Inner Mongolia Muxin Pharmaceutical Co., Ltd., Tianma (Anhui) Guoyao Technology Co., Ltd., Hunan Songlingtang Traditional Chinese Medicine Pieces Co., Ltd., Hunan Honghua Traditional Chinese Medicine Pieces Co., Ltd., and Hainan Shounanshan Ginseng Industry Co., Ltd., failed due to excessive sulfur dioxide residue and incorrect content determination. Additionally, five batches of cold and fever-reducing granules produced by Anyang Lude Pharmaceutical Co., Ltd. were substandard regarding moisture content and fill weight variation, indicating potential issues with stability and accurate dosing.The regulatory framework for these actions stems from the *Drug Administration Law of the People's Republic of China*. As a result, immediate control measures were implemented, including sealing and seizing the affected drugs, mandating product recalls, and requiring companies to suspend sales and use, and initiate rectification. Provincial drug regulatory authorities are tasked with investigating these companies for illegal activities related to producing and selling substandard drugs. These investigations must conclude within three months, with findings made public, emphasizing accountability and consumer safety.

Company: https://www.globalkeysolutions.net/companies/xiangyang-honghua-traditional-chinese-medicine-pieces-co-ltd/762b8b23-faa7-428e-9781-837ca25a0a45/